Search Orphan Drug Designations and Approvals
-
| Generic Name: | efgartigimod alfa-fcab | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Vyvgart | ||||||||||||||||
| Date Designated: | 09/20/2017 | ||||||||||||||||
| Orphan Designation: | Treatment of myasthenia gravis | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
argenx BV Industriepark Zwijnaarde 7 Zwijnaarde 9052 Belgium The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | efgartigimod alfa-fcab |
|---|---|---|
| Trade Name: | Vyvgart | |
| Marketing Approval Date: | 12/17/2021 | |
| Approved Labeled Indication: | treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | |
| Exclusivity End Date: | 12/17/2028 | |
| Exclusivity Protected Indication* : | treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | |
| 2 | Generic Name: | efgartigimod alfa-fcab |
|---|---|---|
| Trade Name: | Vyvgart | |
| Marketing Approval Date: | 05/08/2026 | |
| Approved Labeled Indication: | treatment of adult patients with generalized myasthenia gravis (gMG) | |
| Exclusivity End Date: | TBD | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







